Acrux Stock

Acrux EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Acrux (ACR.AX) as of Jul 16, 2026 is -0.87. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -0.88 — a change of -1.15% (higher).

EV/EBIT

-0.87

YoY

-1.15%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Acrux is 2026 -0.87 . EV/EBIT (Enterprise Value to EBIT) of Acrux was 2025 -0.88 . It decreases by -1.15% higher compared to the previous year.

The Acrux EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-3.80 base
Jan 1, 2020
-2.92 base
Jan 1, 2021
-1.72 base
Jan 1, 2022
-2.07 base
Jan 1, 2023
115.64 base
Jan 1, 2024
-1.72 base
Jan 1, 2025
-0.94 base
Jan 1, 2026 (e)
0.37 base
YEARPRICE-TO-EBIT
2026 est 0.37
2025 -0.94
2024 -1.72
2023 115.64
2022 -2.07
2021 -1.72
2020 -2.92
2019 -3.80
2018 -2.91
2017 2.26
2016 2.74
2015 7.51
2014 4.74
2013 43.01
2012 101.40
2011 5.63
2010 11.62
2009 -41.76
2008 -17.17
2007 -25.32
2006 -10.18
Access this data via the Eulerpool API

Acrux Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Acrux's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Acrux's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Acrux's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Acrux grows earnings faster than its peers.

Acrux Stock analysis

What does Acrux do? Acrux Ltd is an Australian pharmaceutical company specializing in the development and marketing of products in the dermatology field. The company was founded in 1998 and is headquartered in Melbourne. Its history begins with the development of a groundbreaking technology called the "Sprayform® Technology," which allows the administration of liquid medications in spray form, providing numerous advantages compared to traditional administration methods. Acrux obtained the first patent for this technology in 1999 and worked on bringing it to the market. Its business model focuses on licensing its Sprayform® Technology to third parties to advance the development and marketing of products in various therapeutic areas. The company has an experienced research and development team that collaborates closely with partners to develop tailored solutions and support the entire development process, ensuring that all products meet the highest quality standards and regulatory requirements. Acrux Ltd is divided into various divisions, including products for women, diabetes, pain and inflammation, as well as neurology and psychiatry. With its Sprayform® Technology, the company has developed unique therapeutic solutions that meet patients' needs. For example, a testosterone preparation for women has been developed that is simply applied as a spray and offers higher efficacy than traditional tablets. Another product is a fast-acting pain reliever that is administered through a nasal spray. Acrux Ltd also has partnerships with major pharmaceutical companies such as Eli Lilly, Johnson & Johnson, Pfizer, and Sanofi. These partnerships enable Acrux to market its technology globally and offer its customers a comprehensive portfolio of tailored solutions. The partner is granted exclusive rights to use the technology for specific products and markets, facilitating the development of new products and the expansion into new regions. Overall, Acrux Ltd has achieved a leadership position in the field of transdermal systems and transmucosal technologies through its innovative Sprayform® Technology. The company aims to further expand its leadership position by focusing on the development of new products and collaboration with partners. Acrux remains in constant exchange with the scientific community to incorporate the latest research and development insights into its products. Acrux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrux stock

EV/EBIT (Enterprise Value to EBIT) of Acrux is -0.87 in 2026.

Access this data via the Eulerpool API

Valuation — Acrux

All Key Metrics — Acrux